Artes Medical - Worst Pharma Stocks of 2007

Company: Artes Medical
Starting stock price: $8.33
Ending stock price: $2.27
Percent Change: -72.75%

Details: Artes Medical develops and markets injectable products for cosmetic use by dermatologists and plastic surgeons. Its first product, ArteFill, won FDA approval in October 2006 and started shipping in 2007. It competes with collagen injections and Botox.

Artes Medical - Worst Pharma Stocks of 2007
Read more on

Suggested Articles

Horizon Therapeutics has notched an FDA approval for its rare eye disease med Tepezza (teprotumumab), a possible blockbuster drug in the making.

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

After Clovis’ Rubraca snagged an FDA boost in prostate cancer last week, AZ and Merck’s rival Lynparza has matched it with a boost of its own.